Highly Efficient Olefin-Metathesis Catalysts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Highly Efficient Olefin-Metathesis Catalysts
The authors describe the Piers' catalysts and detail latest progress in olefin-metathesis catalyst technology.


Pharmaceutical Technology



Figure 1 (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
Olefin metathesis provides an efficient method for the construction of carbon-carbon double bonds. Significant progress in catalyst development and applications has been made during the past 15 years (1–5). One recent advancement in olefin-metathesis catalysts has been reported by the group of Prof. Warren E. Piers with their synthesis of novel 4-coordinate metathesis catalysts possessing an open coordination site trans to the phosphine or the N -heterocyclic carbene ligand (see Figure 1) (6, 7). These novel, 4-coordinate metathesis catalysts directly mimic the active 14-electron olefin-metathesis catalytic species and negate any prior ligand dissociation step that is necessary with the original 5-coordinate Grubbs- and Hoveyda-type catalysts. Piers' catalysts are active at low temperatures, which makes them particularly useful in inhibiting double-bond migrations (8–12). These new catalysts have contributed to the increasing importance of olefin metathesis as highly functional-group tolerant and as a user-friendly synthetic methodology.

Olefin metathesis in pharmaceutical applications


Figure 2 (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
In recent years, olefin metathesis has been increasingly used by the pharmaceutical industry to synthesize biologically active molecules. Notably, K.C. Nicolaou's group described the syntheses of a variety of complex biologically active molecules using olefin metathesis as the key step (5, 13). Merck reported the synthesis of a NK-1 inflammation drug candidate in which double ring-closing metathesis (RCM) was used to build a key spirocyclic intermediate (see Figure 2) (14). Eisai reported the use of both RCM and cross metathesis (CM) in the synthesis of pladienolide (see Figure 3) (15). Eisai showed that cross-metathesis was successful when the traditional Julia–Kocienski coupling failed to produce the desired product


Figure 3 (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
This article describes the latest progress in olefin-metathesis catalyst technology for applications in both the pharmaceutical and fine-chemical industries and highlights the discovery and use of the new 4-coordinate, 14-electron Piers' olefin-metathesis catalysts.

Olefin-metathesis catalysts


Figure 4 (ALL FIGURES ARE COURTESY OF THE AUTHORS.)
During the past 15 years, major progress has been made in advancing ruthenium olefin-metathesis catalysts. The majority of these new metathesis catalysts were based on ligand modification of well-defined and widely employed Grubbs and Hoveyda ruthenium catalysts (see Catalysts 3, 4, 5, Figure 4) (16–18). Most recently, metathesis catalysts (see Catalysts 6 and 7, Figure 5) were developed to address the need for the highly efficient synthesis of hindered olefins, particularly for RCM reactions forming tetrasubstituted cycloalkenes (see Figure 5) (19, 20).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here